ORG-21465
ORG-21465 is a sedative drug that was developed by Organon International in the 1990s. It is a steroid derivative, specifically a neuroactive steroid, which has anxiolytic and anticonvulsant effects.
History[edit | edit source]
ORG-21465 was first synthesized by Organon International, a global pharmaceutical company based in the Netherlands. The company was known for its innovative research and development in the field of pharmaceuticals. ORG-21465 was one of the many drugs developed by the company during its active years.
Pharmacology[edit | edit source]
ORG-21465 is a neuroactive steroid, a group of steroids that have effects on the nervous system. It acts as a positive allosteric modulator at the GABA_A receptor, the major inhibitory neurotransmitter receptor in the brain. This action enhances the inhibitory effects of GABA, leading to the sedative and anxiolytic effects of the drug.
Clinical Use[edit | edit source]
The primary use of ORG-21465 is as a sedative for the induction of anesthesia in surgical procedures. It has a rapid onset of action and a short duration of effect, making it suitable for this purpose. It is also used for the treatment of anxiety disorders due to its anxiolytic effects.
Side Effects[edit | edit source]
Like other sedative drugs, ORG-21465 can cause a range of side effects. These can include drowsiness, confusion, and impaired motor coordination. In rare cases, it can cause more serious effects such as respiratory depression and dependence.
See Also[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD